# The Drug Rediscovery Protocol (DRUP Trial)

> **NCT02925234** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 1550 (estimated)

## Conditions studied

- Cancer
- Tumors
- Neoplasm
- Neoplasia

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Olaparib
- **DRUG:** Dabrafenib
- **DRUG:** Nilotinib
- **DRUG:** Trametinib
- **DRUG:** Erlotinib
- **DRUG:** Trastuzumab and Pertuzumab (combination treatment)
- **DRUG:** Vemurafenib and Cobimetinib (combination treatment)
- **DRUG:** Vismodegib
- **DRUG:** Regorafenib
- **DRUG:** Nivolumab
- **DRUG:** Afatinib
- **DRUG:** Dabrafenib and trametinib
- **DRUG:** Ribociclib
- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab
- **DRUG:** Durvalumab
- **DRUG:** Rucaparib
- **DRUG:** Axitinib
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT02925234
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-08
- **Primary completion:** 2027-09
- **Final completion:** 2027-12
- **Target enrollment:** 1550 (ESTIMATED)
- **Last updated:** 2024-01-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02925234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02925234, "The Drug Rediscovery Protocol (DRUP Trial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02925234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*